Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS store will be under maintenance Saturday, 7 December between 6 AM and 12 PM. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 08 July 2014 | By Alexander Gaffney, RAC,
US regulators have announced they will soon hold their tenth patient-focused drug development meeting, this time focusing on a collection of blood and platelet disorders that includes hemophilia A, hemophilia B, and von Willebrand disease.
The meetings are required under the Food and Drug Administration Safety and Innovation Act (FDASIA), Section X of which called for the US Food and Drug Administration (FDA) to meet with patients in order to better understand their perspectives on the safety and efficacy of therapies.
In particular, the legislation envisions FDA focusing on disease areas with inadequate treatment options or diseases with no recognized treatments. The thinking of legislators and advocates of the law was that some patients might be more willing to accept risky or unproven treatments given a dearth of acceptable alternative options.
Including today's announcement, FDA has announced patient-focused drug development meetings for ten disease groups:
FDA's newest meeting will focus on a "diverse group" of heritable blood and platelet disorders, such as hemophilia A and B, von Willebrand disease, factor VII and XIII deficiencies, α2-antiplasmin deficiency and Gray platelet syndrome.
As with other disease groups, FDA has a specific list of questions it intends to ask of patients—a list of questions that shares much in common with other disease-specific meetings.
Interestingly, the current batch of questions also bucks a recent trend toward FDA asking fewer questions. The last two meetings announced by FDA, focusing on Idiopathic Pulmonary Fibrosis (IPF) and Inborn Errors of the Metabolism, had asked just eight and six questions, respectively. FDA's blood disorders meeting will ask 12 questions of patients.
The meeting will take place on 22 September 2014 at FDA's White Oak Campus in Silver Spring, MD.
FDA Federal Register Notice
Tags: Patient-Focused Drug Development, PFDD, FDASIA, Patients, Blood, Platelet
Regulatory Focus newsletters
All the biggest regulatory news and happenings.